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Abstract: Immune thrombocytopenic purpura (ITP) is an autoimmune disorder that is 
  characterized by antibody-mediated platelet destruction and decreased platelet production. ITP 
and its treatments have been recognized to cause diminished quality of life in those afflicted 
with this illness on levels comparable to other chronic diseases. The disease can be self-limiting, 
but in adults it often is a chronic process requiring medical intervention to maintain appropri-
ate platelet counts and to reduce bleeding events. Many patients go on to develop disease that 
is refractory to current interventions. Historically, the aim of treatment has been focused on 
reducing the amount of antibody-mediated destruction but newer therapies have centered on 
the decreased platelet production. Two new medications that target production of platelets have 
recently been USA, Food and Drug Administration (FDA) approved for the treatment of chronic 
relapsing ITP. Here, we provide an overview of ITP and a comprehensive review of the newest 
therapies aimed at the stimulation of platelet production.
Keywords: immune thrombocytopenic purpura, therapy, thrombopoietin, romiplostim, 
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Introduction
Immune thrombocytopenic purpura (ITP) is an autoimmune disorder that is charac-
terized by antibody-mediated platelet destruction and impaired platelet production 
causing thrombocytopenia and increased risks of bleeding.1 It remains a diagnosis 
of exclusion and is primarily based on the patient’s history, physical examination, 
complete blood count, and peripheral smear.2 While childhood ITP typically presents 
as an acute, self-limited process, adult disease tends to be persistent with recurrent 
relapses often requiring medical intervention. The clinical presentation is variable. 
Up to 21% of adults are asymptomatic and may be diagnosed incidentally after routine 
blood work, yet many present with mucocutaneous bleeding, hemorrhage from other 
body sites, or in rare cases suffer life-threatening hemorrhage; the most serious being 
intracranial.3 Signs and symptoms usually correlate with platelet count levels. Normal 
platelet counts range from 150 × 109/L to 450 × 109/L (new recommendations suggest 
a lower threshold of 100 × 109/L),4 yet most patients do not exhibit signs of bleeding 
until platelet counts are 50 × 109/L.1
The true incidence of adult ITP has not been well established and varies based on 
the definition of the platelet count threshold. Most epidemiologic studies originate 
from Europe while data remains limited in the United States. The incidence of adult 
ITP has been reported to range from approximately 1.6 to 3.9 per 100,000 persons 
per year with a notable increased incidence with age.3,5,6 The median age of onset is Journal of Blood Medicine 2010:1 22
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56 years and female to male ratio is slightly greater (1.7) in 
those less than 60 years but is equal among older patients.3,7 
The prevalence of this disease in the United States and 
Europe is estimated at 9.5 per 100,000 persons per year but 
has been reported up to 20 per 100,000 persons if patients 
over the age of 65 are included, causing significant clinical 
and economic impact.8,9 The morbidity and mortality risk 
of patients with ITP is 30%–50% higher than those without 
the disease.6,10 ITP leads to increased hospitalizations, spe-
cialty consultations, medications, and surgery in addition to 
decreased quality of life.11–13 Therefore, improvements in the 
current therapies to achieve and maintain a durable platelet 
count, reduce bleeding risks, and minimize treatment related 
toxicities remains a priority.
Although the precipitating etiology behind ITP is unclear, 
the pathogenesis of platelet antibody formation leading to 
destruction and suppressed platelet production has been well 
studied. Proposed mechanisms describe an intricate rela-
tionship between B and T-cells in the formation of antibody 
production.14,15 Anti-platelet antibodies arise from a limited 
number of B-cell clones that target platelet glycoproteins 
(GP) IIb/IIIa and Ib/IX. The glycoproteins are cleaved to 
peptides by macrophages or other antigen-presenting cells 
(APC) and are expressed on MHC class II molecules by way 
of Fcy receptors. Additionally, the APC generate new epitopes 
which induce activation of T-cells. This epitope-spreading is 
thought to play an important role in the initiation of ITP. The 
presentation of peptides on the APC triggers the binding of 
T-cell receptors (TCR) which activate T helper cells. The 
T helper cell then stimulates the production of cytokines 
(IL-2 and interferon) thus promoting B-cell differentiation 
and autoantibody production.16 The antibodies opsonize the 
platelets which are then destroyed by macrophages, primarily 
in the spleen. These antibodies also bind to megakaryocytes 
which can inhibit maturation and platelet production.14,16,17 
Although testing for these antibodies is not considered 
standard of care, some studies propose that autoantibody 
detection in patients suffering from ITP may correlate with 
disease severity and prognosis. Further evaluation is needed 
in this regard.18,19
Indications for treatment  
and first line agents
Treatment is indicated in those with platelet counts   
30 × 109/L, or in those with counts 50 × 109/L with 
evidence of mucocutaneous bleeding or with risk factors 
for bleeding.2 The goals of therapy are aimed at maintaining 
appropriate platelet counts and reducing the risk of bleed-
ing while minimizing treatment-related toxicities. Initial 
therapy is usually focused on inhibition of antibody platelet 
destruction and includes treatments such as corticosteroids, 
IVIG, and anti-RhD immunoglobulin (Table 1).20,21 Predni-
sone (1–4 mg/kg/day) is the standard initiation therapy with 
nearly a 66% complete or partial response rate in the first 
1–2 weeks.2,20 However, relapse is often seen in adult chronic 
disease and adverse effects of long-term use of corticosteroids 
needs to be considered. IVIG (1 g/kg/day for 1–2 days) is 
often reserved for those who do not respond to corticosteroids 
or other similar therapies and can be used when a rapid or 
temporary increase in platelets is needed. The results, while 
effective in approximately 85% of patients, are transient and 
often last an average of 3–4 weeks.22 Anti-D immunoglobulin 
(50 µg/kg) is approximately 70% effective in Rh-positive, 
nonsplenectomized patients.23 It also has a transient effect 
Table 1 Available initial treatment options for patients with iTP, including splenectomy
Therapy Dose Time to peak 
response (days)
Response duration  
(average)
Initial  
responses (%)
Complete  
remission (%)
Adverse effects
Oral  
corticosteroids
1–4 mg/kg/d 28 2–6 weeks 66 16 Hypercortisolism: 
diabetes, infections, 
osteoporosis
intravenous 
  immunoglobulin
0.4 g/kg/d × 5  
1 g/kg/d × 2
2–4 3–4 weeks 75–92 50–65 Headache, lethargy, 
fever, photophobia
Anti-D  
  immunoglobulin
50 µg/kg/d × 1 3 3 weeks 70 33 Mild expected 
extravascular 
hemolysis, fever 
headache, nausea, 
chills, dizziness
Splenectomy 
 
 
 
10 
 
7 years 
 
60–86 
 
60 
 
Surgical  
complications,  
sepsis, thrombosis
Notes: Current first line therapies and splenectomy for the initial treatment of ITP.2,3,17,18Journal of Blood Medicine 2010:1 23
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on platelets and is utilized when a temporary increase in 
platelets or temporary deferral of splenectomy is warranted.24 
Although these therapies are often effective, their duration 
tends to be short-lived. Each of these treatments aims at creat-
ing a complete or partial remission in thrombocytopenia and 
do not appear to change the natural history in the disorder. 
Due to the relapsing, chronic nature of adult ITP, frequent 
use of these medications may occur. Long-term side effects 
of each agent must be considered and is a factor that patients 
often refer to when rating their quality of life.13,25
Second line therapy
While most patients have transient responses after initial 
therapy, some will have relapsing disease that with time, 
have less response to the preliminary medications. Tradition-
ally splenectomy has been the most successful second line 
therapy with the highest rate of durable platelet response 
with long-term follow-up. After splenectomy, 66% of 
patients acquire normal platelet counts that are durable up 
to 7.3 years following the procedure.26 Overall failure rates 
5 years post-splenectomy are approximately 28%. Short-term 
failure occurs in 8.2% of patients while the long-term relapse 
rate is near 44 per 1000 patient years with most occurring in 
the first two years post-operatively.27 Splenectomy remains 
an invasive procedure that carries some operative risks. 
Mortality rates of 1% and 0.2% post-open laparotomy and 
laparoscopic splenectomy, respectively, have been reported.26 
Small lifetime risks of serious infections are known and some 
patients are not candidates or may prefer not to undergo 
surgery.27 Alternative therapies are indicated in those not 
able to receive a splenectomy, in those who do not respond 
to the splenectomy, or those that have relapse of disease 
post-operatively.
Treatment of chronic  
refractory ITP
Chronic refractory disease occurs in less than 10% of ITP 
patients and is defined as disease that persists for greater 
than 12 months.4,10 It is characterized as failure to achieve a 
response post-splenectomy requiring continuous treatments 
to minimize risk of clinically significant bleeding. Diagnosis 
can only be made after all other causes for thrombocytopenia 
have been eliminated.4 Patients who go on to have refractory 
disease have nearly a 4-fold increase in the risk of death.10
Therapeutic agents intended for use in refractory 
cases have included high dose corticosteroids such as 
dexamethasone, or agents such as danazol, azathioprine, 
cyclosporine, cyclophosphamide, vinca alkaloids, and 
combination chemotherapy. Recent data suggests the 
combination of individual immunosuppressant agents 
may have an additional benefit in refractory patients.28 
However, each treatment carries its own side effects and 
evidence is still lacking from randomized clinical trials. 
Therefore use should be limited to those with refractory 
disease with appropriate clinical judgment behind their 
application.2,20
Minimal work had been done in the area of immuno-
therapy for ITP until the development of anti-CD20 anti-
body. Rituximab, a monoclonal anti-CD20 antibody, has 
been recently introduced as a possible therapeutic agent for 
the treatment of ITP. Rituximab targets antibody producing 
B lymphocytes and lyses the culprit cell behind the auto-
antibody production, therefore proving to be a potential tool 
in the treatment of ITP. Several studies have been performed 
to test the efficacy and safety of Rituximab in the treatment 
of ITP. Collaborative review of 19 small studies reported 
an overall response rate of 62.5% with a mean duration of 
10.5 months in patients who received 4 weekly infusions 
of 375 mg/m2. Sixty percent of patients in the largest of 
these studies reported mild infusion-related side effects   
and approximately 7% reported unfavorable outcomes.29 
A recent cohort analyzing 23 patients revealed a less prom-
ising outcome with only a 48% response to Rituximab, yet 
reported a higher rate of serious adverse events (17%).30 
A randomized study comparing Rituximab plus Dexametha-
sone or Dexamethasone alone in ITP yielded a favorable 
platelet count response with the combination therapy without 
worsening the safety profile, suggesting this dual treatment 
as a reasonable option prior to splenectomy.31 Further large 
randomized controlled trials are still needed to investigate 
the utility of Rituximab in ITP.
Thrombopoietin (TPO) and the 
development of TPO agonists
For many years, focus has been on the elimination and sup-
pression of the auto-antibodies that cause platelet destruction, 
but a newer shift has targeted the mechanism behind the 
decreased platelet production in attempts to enhance platelet 
counts. In patients with ITP, it has been well documented that 
auto-antibodies also interfere with megakaryocyte matura-
tion and platelet production.32 Thrombopoietin (TPO) is a 
glycoprotein primarily produced in the liver that has been 
recognized as the principal cytokine regulator of megakaryo-
poiesis and platelet production.33 TPO acts by binding to its 
c-MPL receptor (a receptor present on multilineage human 
myeloid progenitors) and triggering a signaling cascade via Journal of Blood Medicine 2010:1 24
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JAK2 and STAT5 signal transduction resulting in increased 
megakaryocyte proliferation and differentiation, thus 
enhanced platelet production.33–35 TPO levels in patients with 
ITP are usually normal or only mildly elevated, but much 
less than expected for the degree of thrombocytopenia. In 
fact, TPO levels were markedly lower than levels found in 
patients with thrombocytopenia from chemotherapy or bone 
marrow failure.36 One explanation suggests that patients 
with ITP have a rapid clearance of TPO either by binding 
to platelets undergoing rapid consumption or by binding 
to increased megakaryocytes in this disease.37 This finding 
prompted investigation into methods to enhance platelet 
production.
In 1994, thrombopoietin was successfully cloned lead-
ing to the production of two new therapies: recombinant 
human TPO (rhTPO), a glycosylated molecule identical to 
endogenous TPO, and recombinant human megakaryocyte 
growth and development factor (MGDF) which is a truncated 
nonglycosylated form of TPO, conjugated to polyethylene 
glycol (PEG-rHuMGDF).38,39 Both agents were able to 
increase platelet counts in normal subjects as well as patients 
undergoing chemotherapy.40 In an initial clinical study of 
PEG-rHuMGDF in ITP, results were promising with a 75% 
response rate.41 However, a subsequent larger clinical trial 
revealed this agent was associated with prolonged throm-
bocytopenia. Data indicated the development of antibodies 
to PEG-rHuMGDF in healthy volunteers that cross-reacted 
to endogenous TPO, which caused severe persistent throm-
bocytopenia in select patients. These findings required its 
removal from clinical studies.42
Despite this setback, these agents demonstrated efficacy 
in increasing the platelet count in thrombocytopenic patients 
by targeting the TPO receptor, therefore efforts next focused 
on the development of TPO receptor agonists that do not 
stimulate this antibody production. Researchers reviewed 
peptide libraries to find random, unrelated peptide and 
nonpeptide molecules that could stimulate TPO receptors 
without causing antibody production.43,44 This strategy led 
to the development of two TPO mimetic drugs, romiplostim 
and eltrombopag, which have no sequence homology with 
endogenous thrombopoietin.37,45 Both agents work by mim-
icking thrombopoietin and act by binding to or near the 
TPO receptor, stimulating megakaryopoiesis and platelet 
production. The quality of multiple randomized studies as 
outlined below for both romiplostim and eltrombopag have 
led to recent FDA approval of these agents for use in refrac-
tory ITP both before and after splenectomy, and are under 
continuous clinical investigations at this time.
Romiplostim (AMG 531)
Romiplostim (AMG 531; Nplate®) is a thrombopoietin 
receptor agonist that received FDA approval in August 
2008 for the treatment of thrombocytopenia in patients with 
chronic ITP who have had insufficient response to steroids, 
IVIG or splenectomy.45–47 It is comprised of an Fc-peptide 
fusion protein (peptibody) containing disulfide-bonded 
human IgG1 heavy chain, and kappa light chain constant 
regions making up an Fc component which extends the 
half-life of the molecule to 120–160 hours (Figure 1).48 This 
component is linked with two identical peptide sequences 
containing thrombopoietin receptor-binding domains mak-
ing it capable of binding and activating the TPO receptor 
(c-MPL), thus stimulating megakaryopoiesis and platelet 
production.46,49 This structure has no sequence homology 
with human TPO and therefore does not develop cross-
reacting antibodies to thrombopoietin.45,50
Safety and tolerance were analyzed and deemed 
adequate in a preliminary double-blinded, randomized, 
placebo-controlled human trial using a single injection of 
AMG 531 at varied doses allowing for Phase I and II trials 
of romiplostim.49,51–53 The Phase I study administered two 
injections of romiplostim to 24 patients at incremental doses 
to assess safety and tolerability as well as to determine which 
dose that would achieve a platelet count within the targeted 
range of 50 × 109/L to 450 × 109/L. Platelet response did 
not reach the target in patients who received doses less than 
3 µg/kg, while 7 patients receiving 3, 6, or 10 µg/kg reached 
or exceeded the goal. The most frequently reported adverse 
events were contusions and ecchymosis (67%) and mild to 
moderate headache (46%). No major adverse events were 
attributed to the use of romiplostim. One patient, however, 
reported a transient decrease in platelets after discontinuation 
of the medication.52
The Phase II study then randomly assigned 21 patients 
to receive incremented doses of AMG 531 once a week 
Fc carrier domain Peptide receptor-binding domain 
Figure 1 Structure of romiplostim.48
Notes: The left-hand side of the diagram shows the igG Fc carrier portion of the 
molecule. The right-hand side shows the peptide that binds to the thrombopoietin 
receptor (Mpl).Journal of Blood Medicine 2010:1 25
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for 6 weeks. Platelet counts increased in most patients with 
the targeted goal being met or exceeded in 12 of 16 patients 
receiving romiplostim. The most frequently reported adverse 
events were contusions and ecchymosis (59%), expistaxis 
(41%), and mild to moderate headache (29%). During the 
study, one patient receiving romiplostim suffered a severe 
adverse event described as vaginal bleeding with transient 
worsening of thrombocytopenia 19 days after discontinua-
tion of romiplostim.52
The ongoing rate of platelet destruction did not appear 
to be affected by romiplostim, as all patients who received 
the drug had a platelet count that returned to baseline 
(or transiently below baseline) after discontinuation of 
therapy. These preliminary short-term studies indicated that 
romiplostim causes a dose-dependent increase in platelet 
counts that is generally well-tolerated with no anti-TPO or 
anti-AMG 531 antibodies detected. This prompted the need 
for further investigation into individual dose adjustment 
therapy, as well as the outcome of long-term therapy and its 
ability to maintain a durable platelet response.
Two parallel Phase III randomized, placebo-controlled, 
double-blind clinical trials assessed the efficacy, as measured 
by a durable platelet response of 50 × 109/L for 6 or more of 
the last 8 weeks, safety, and optimal dosing in the long-term 
administration of romiplostim.54 Sixty-three splenectomized 
and 62 nonsplenectomized patients with a mean of 3 plate-
let counts 30 × 109/L were enrolled. A durable platelet 
response was achieved in 16 of 42 splenectomized patients 
versus 0 of 21 placebo, and by 25 of 41 nonsplenectomized 
patients versus 1 of 21 placebo. The overall platelet response 
(transient or durable) was 79% of splenectomized and 88% 
of nonsplenectomized patients given romiplostim compared 
to 0% and 14% of those receiving placebo, respectively. In 
addition to monitoring platelet response, patient capacity to 
reduce or discontinue concurrent therapy during this trial 
was assessed. Eighty-seven percent of patients receiving 
romiplostim were able to reduce or discontinue concomi-
tant therapy compared to 38% of the placebo group, while 
maintaining a durable platelet response.5
Adverse events were reported in 95% of those receiving 
placebo and 100% of those receiving romiplostim, but the 
majority were considered to be mild to moderate. Serious 
adverse events were noted in four patients, two thought to be 
romiplostim related. One romiplostim-assigned patient devel-
oped thrombosis while another splenectomized patient with 
a baseline elevated bone marrow reticulin developed further 
reticulin after 7 weeks of therapy. The levels did return to 
baseline 14 weeks after discontinuation of the medication.54
Patients who completed this or other AMG 531 studies 
were then eligible to enroll in an open-label extension study 
with weekly injections and dose adjustment based on indi-
vidual platelet counts over a longer period.55 To date, this 
study has investigated 142 patients undergoing treatment with 
romiplostim for up to 156 weeks, (mean 69 weeks) using a 
dose-adjusted weekly administration to achieve a sustainable 
target platelet count of 50 to 250 × 109/L. After 3 weeks of 
therapy, 51% of patients had demonstrated a targeted plate-
let response while 87% of patients had at least one targeted 
response during the study. Long-term results of this study are 
still pending. This trial did demonstrate a decreased propor-
tion of responses in splenectomized patients and although 
goal platelet counts were reached, these were generally less 
than in the nonsplenectomized patients. This discrepancy 
raises a question of whether romiplostim could be used to 
avoid splenectomy and this is currently being investigated.55 
The average weekly dose was 5.9 µg/kg; somewhat higher 
than the 2.5 µg/kg seen in the Phase III trials. Rescue medica-
tions were needed in 36% of patients at some point during 
the study, but use decreased with time. Eighty-four percent 
of patients requiring concurrent treatment at baseline were 
able discontinue (50%) or decrease (34%) their medications 
by the time of study cut-off. These results were reinforced 
by another similar study which pooled data from these 2 
phase III trials and found that only 14% of patients receiving 
romiplostim required IVIG rescue therapy compared to 50% 
in the placebo group.56
The most frequently reported adverse events were head-
ache, contusion, and expistaxis. Nineteen serious adverse 
events were noted in 13 patients including increased bone 
marrow reticulin, vaginal hemorrhage, deep venous throm-
bosis, and monoclonoal gammopathy of undetermined 
significance. Bleeding events decreased, however, from 
42% to 29% from the first 24 weeks to the next.55,57 Fourteen 
severe bleeding events occurred, but no deaths were reported 
from bleeding. Twelve thrombotic events were reported 
in 7 patients; 6 of the 7 patients had known risk factors 
for thrombosis prior to romiplostim. There were 3 deaths 
reported during this study, none of which were attributed to 
romiplostim therapy.
During this extended study, a total of 16 patients under-
went evaluation to assess romiplostim’s effect on bone 
marrow reticulin. Eight baseline biopsies were obtained, 
with 5 of 7 remaining negative after treatment. Spontaneous 
reports from 8 additional patients revealed increased bone 
marrow reticulin after therapy. Follow up bone marrows 
were completed in 2 of these patients upon discontinuation Journal of Blood Medicine 2010:1 26
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of romiplostim, 1 of which demonstrated improvement. No 
clinical symptoms were reported in any of the cases, how-
ever.55 Reticulin is a normal component of the bone marrow 
and can be found in healthy subjects in small amounts. 
Increases can occur in many benign and malignant conditions 
and it is proposed that thrombopoietic agents may reversibly 
increase bone marrow reticulin by releasing transforming 
growth factor (TGF)-B from the increased number of bone 
marrow megakaryocytes.58,59 Further investigations into the 
relationship between bone marrow fibrosis and romiplostim 
have been performed in animal and human studies, both of 
which demonstrated dose-dependent increases in bone mar-
row reticulin that resolved after discontinuation of therapy 
with time.59 To date, no progression to myelofibrosis has been 
reported in any patient receiving TPO mimetic therapy.60
Overall, the current studies on the safety and efficacy of 
romiplostim suggest that romiplostim may in fact be a well-
tolerated treatment, and perhaps even a maintenance therapy 
for patients with chronic refractory ITP (Table 2). In general, 
patients reported a decrease in bleeding events over time, as 
well as a reduced number of severe bleeding events. This 
suggests that the platelet count responses to romiplostim are 
of clinical benefit, thus making it a useful therapy in patients 
with chronic, refractory ITP.
The recommended starting dose for romiplostim is 
1 µg/kg/week up to a maximum dose of 10 µg/kg/week to 
achieve and maintain a platelet count of 50 × 109/L, as 
necessary, to reduce the risk of bleeding. It should not be 
administered if platelet counts are 400 × 109/L and should 
be discontinued if, after 4 weeks, the platelet count does not 
respond to maximum dosage.61,62 It is currently available in 
single use vials of 250 µg or 500 µg.63
Eltrombopag (SB-497115)
Eltrombopag (SB-497115; Promacta) is an oral, low molecu-
lar weight, nonpeptide thrombopoietin receptor agonist that 
received FDA approval in November 2008 for the treatment 
of chronic refractory ITP in people who have had insufficient 
response to corticosteroids, IVIG or splenectomy (Figure 2).64 
While its effects are similar to romiplostim, its mechanism 
differs in that it binds to the transmembrane domain of the 
thrombopoietin receptor but does not compete for the same 
binding site as endogenous TPO or romiplostim. Instead, it 
activates the JAK2 and STAT5 signaling pathway to stimu-
late proliferation and differentiation of megakaryocytes, thus 
increasing platelet production.65
Pre-clinical activity of eltrombopag confirmed its selective 
nature for TPO receptors in humans with a resultant increase in 
platelet production in vivo without affecting the overall platelet 
function.66,67 Phase I clinical studies in volunteers with normal 
platelet counts and in patients with thrombocytopenia second-
ary to hepatitis C infections, including a placebo-controlled 
Table 2 Comparison of characteristics of romiplostim and eltrombopag
Romiplostim Eltrombopag
route of administration Once weekly subcutaneous injection Once daily oral
Starting dose 1 µg/kg/week 50–75 mg/day
Efficacy Platelet count increases seen at 5 days;  
peak at day12–15
Platelet count increases seen at 7 days; 
peak at day 15
response rates:
  Phase ii 79% 70% 50 mg  
81% 75 mg
  Phase iii 79% Splenectomized  
88% Nonsplenectomized
66%* 50–75 mg**
  extension studies 87% Transient response 79% transient response
Duration of platelet response after  
treatment discontinuation
Platelets return to baseline within 2 weeks Platelets return to baseline within 
2 weeks
effect of previous splenectomy on  
durable platelet response
Slightly more effective if nonsplenectomized  
(51% vs 31%)
No difference
Common reported adverse events Headache, contusion, fatigue, expistaxis,  
arthralgia
Headache, contusion, nausea,  
nasopharyngitis
Other adverse events Transient bone marrow reticulin deposition elevated liver enzymes, possible bone 
marrow reticulin deposition
Presence of cross-reactive antibodies No No
Notes: *59% response with 50 mg and additional 29% response when dose increased to 75 mg. **No statistical difference between splenectomized and nonsplenectomized patients. 
Characteristics of romiplostim and eltrombopag derived from clinical trials.50,51,66,67Journal of Blood Medicine 2010:1 27
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clinical trial in adults assessing the platelet response and 
  tolerability of eltrombopag, have been performed.44 Seventy-
three healthy men with similar demographics were randomized 
to receive oral eltrombopag over a 10 day period with doses 
ranging from 5 mg to 75 mg. The greatest result occurred in 
those receiving 50 mg and 75 mg daily, achieving platelet 
responses greater than 20% above baseline. All platelet counts 
returned to baseline 12 days after the last dose was adminis-
tered. Adverse effects did not differ between treatment and 
placebo groups and were not dose-related.68
Phase II trials aimed to determine whether eltrombopag 
could safely increase platelet counts and reduce bleeding 
events in patients with chronic refractory ITP. A multicenter, 
double-blind, randomized, placebo-controlled trial evaluated 
the effects of once daily oral administration of eltrombopag.69 
The study randomized 117 patients who had received at 
least one previous treatment for ITP and had a platelet count 
of 30 × 109/L into groups to be given 30 mg, 50 mg, or 
75 mg of eltrombopag per day. Response was defined as a 
platelet count of 50 × 109/L by day 43. The greatest results 
were seen in the latter two groups as 81% of patients given 
75 mg and 70% of those given 50 mg achieved the targeted 
platelet count and had decreased incidence of bleeding. 
Platelet counts returned to baseline once the therapy was 
discontinued and analysis revealed there was no difference 
in response between splenectomized and nonsplenectomized 
patients. Adverse event incidence and severity were similar 
across all study groups including placebo. The most common 
of these events reported was mild to moderate headache. Two 
patients receiving 75 mg doses had elevations in aspartate 
aminotransferase. An FDA report on eltrombopag revealed 
that 19 of 117 patients exposed to eltrombopag had bone 
marrow examinations, 7 of which discovered fibrosis.58 This 
study determined that 50 mg and 75 mg were effective for 
short-term treatment of chronic ITP.
With the intention of improving platelet counts, decreasing 
bleeding events, yet reducing therapy-related toxicities, the 
50 mg daily dose of eltrombopag was chosen for further inves-
tigation of efficacy, safety, and tolerability in the Phase III 
clinical trials.70 Efficacy of a dose increase to 75 mg, if needed, 
was also evaluated. One hundred and fourteen patients, 
naïve to TPO mimetics, were randomized in a double-blind, 
placebo-controlled study to receive eltrombopag at 50 mg. 
The primary endpoint was a platelet response to 50 × 109/L 
by day 43. An increase to 75 mg was allowed after 3 weeks 
in those whose platelet counts had not achieved the target. 
Fifty-nine percent of the patients receiving eltrombopag 
met the primary target and demonstrated reduced symptoms 
of bleeding. Of the 74 patients administered eltrombopag, 
34 patients required dose increases to 75 mg with 10 responses 
(29%). In all patients, platelet counts slowly returned to base-
line within 2 weeks of therapy completion and, as expected, 
bleeding events increased with decreasing platelet counts. 
Platelet count improvements were independent of the use of 
concurrent ITP therapy, splenectomy, age, or baseline platelet 
count. Adverse events were similar between placebo and treat-
ment groups with the exception of more nausea and vomiting 
reported in the treatment group. No deaths or thrombosis were 
reported. Six treatment and 1 placebo patient had elevation of 
serum transaminase concentrations to twice the normal limit 
with 1 patient withdrawing from the study due to abnormal 
hepatic function. Two patients classified as nonresponders to 
eltrombopag reported gastrointestinal and cerebral hemor-
rhage. New cataracts were reported in 3 patients receiving 
treatment and 1 placebo patient, while progression of exist-
ing cataracts occurred in 2 treatment patients and 1 placebo 
patient. Pre-clinical studies also revealed risk of cataract 
formation in rats receiving eltrombopag.66
Ongoing analysis continues in the treatment of chronic 
ITP with eltrombopag. An open-label study designed to evalu-
ate the long-term safety and clinical benefit in patients who 
have already been administered eltrombopag called EXTEND 
is being conducted. To date, two hundred seven patients have 
been treated with eltrombopag with doses starting at 50 mg, 
but with the flexibility for titration up to 75 mg or down 
to 25 mg based on platelet counts. Long-term effects were 
similar to those in the shorter studies. Seventy-nine percent of 
patients reached target platelet counts of 50 × 109/L, while 
24% were able to maintain that level for 25 consecutive 
weeks.71 Patients whose platelet counts fluctuated underwent 
evaluation of intermittent treatment with eltrombopag with 
outcomes suggesting that repeated use can provide predict-
able and consistent responses from previous administration.72 
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Figure 2 Structure of eltrombopag.60
Notes: Molecular formula C25H22N4O4.2(C2H7NO). eltrombopag is an orally bioavail-
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Data from 165 chronic ITP patients both refractory (68) and 
nonrefractory (97) have also been assessed. Overall, 75% 
of refractory and 81% of nonrefractory had platelet count 
responses 50 × 109/L with no statistical difference between 
the two. Both groups had diminished bleeding episodes dur-
ing treatment as well.73 Review of patients in the EXTEND 
study who did not achieve platelet counts 50 × 109/L, 
demonstrated that they still receive clinical benefit from the 
medication in terms of doubling platelet counts, reducing 
concurrent medications (up to 80% were able to reduce) and 
reducing bleeding symptoms.74,75
A second Phase III trial, RAISE, evaluated the long-
term efficacy and safety of eltrombopag in 197 patients in 
a randomized, double-blind, placebo-controlled study over 
6 months, with the primary end point being the odds of plate-
let response during the treatment period. Of the 197 enrolled, 
135 patients were assigned to eltrombopag at 50 mg with 
the ability to increase or decrease the dose based on platelet 
counts.76 Those receiving the medication were calculated to 
be eight times more likely to achieve a targeted response. 
Concurrent therapy was reduced in 59% of those receiving 
eltrombopag and patients responded to treatment despite 
splenectomy status, previous platelet counts, or concomitant 
medications used. Adverse events were similar to previous 
studies and were comparable between placebo and treatment 
groups with the most common reported adverse event being 
mild to moderate headache. No evidence of bone marrow 
fibrosis was detected in clinical or laboratory assessment. 
Serum hepatobiliary abnormalities were detected in 13% of 
patients receiving eltrombopag.76
Eltrombopag is metabolized in the liver and may be 
associated with hepatotoxicity.65 In fact, the FDA issued a 
black box warning regarding this risk, recommending initial 
and routine monitoring of liver function tests.64 Patients with 
known hepatic impairment need to be monitored closely with 
administration of this medication and initial dosing should be 
reduced to 25 mg/day.65 Clinical studies in healthy volunteers 
indicate that eltrombopag is not an inducer or inhibitor of the 
cytochrome P (CYP) isoenzymes, but no studies have evalu-
ated the effects other CYP isoenzyme inducers or inhibitors 
have on its metabolism.64 In vitro studies have suggested that 
it is an inhibitor of the UDP-glucuronosyltransferase (UGT) 
isoenzymes (enzymes responsible for metabolizing medica-
tions such as acetaminophen, narcotics, and NSAIDs), but 
again, no clinical studies comparing co-administration have 
been performed.64
Food and antacids affect the pharmacokinetics of 
eltrombopag.77 It has a similar structure to some metal 
chelators and can therefore bind to metals such as zinc, 
copper, magnesium, and calcium. Two single-dose open-
label randomized sequence crossover studies evaluated the 
bioavailability of eltrombopag when administered with 
different foods, fat levels, calcium levels, and antacids. 
Men receiving a high calcium diet with administration 
of eltrombopag had a 59% reduction in bioavailability 
and those administered a metal cation-containing antacid 
had a 70% reduction.77 Current guidelines recommend 
taking this medication on an empty stomach to enhance 
bioavailability.65
Overall, eltrombopag appears to be a well-tolerated thera-
peutic option for patients with chronic refractory ITP and has 
shown to have short and long-term benefits for increasing 
platelet counts to safer levels and reducing the occurrence of 
bleeding events with relatively mild adverse effects (Table 2). 
Its efficacy is similar to that of romiplostim and affords an 
alternative agent in this class of medications.
Quality of life in patients using  
TPO mimetic agents
The focus of ITP typically revolves around the etiology, 
mechanisms, and treatment of the disease. Often, the qual-
ity of a patient’s life, who is suffering from chronic ITP, is 
overlooked. ITP is often considered a benign disease, yet 
health-related quality of life is frequently reported as poor.78 
The symptoms and treatment of ITP can have a significant 
impact on a person’s daily functioning. Likewise, there are 
psychological components, such as fear of bleeding, body 
image, fear of surgery, and medication side effects which 
may have a negative influence on the patient’s life. A study 
of 73 adult patients with chronic ITP was performed to assess 
the impact of the disease via a self-reported, health-related, 
quality of life questionnaire.78 The questionnaire assessed 
8 components of quality of life including physical function-
ing and role, bodily pain, general health, vitality, emotional 
role, social functioning, and mental health. It compared 
results of ITP patients to those without disease, with a dif-
ferent chronic disease, and those receiving medications or 
not. Results revealed that patients with ITP had a diminished 
sense of quality of life compared to healthy individuals, 
similar quality to those with chronic diseases such as diabetes 
or arthritis, with results mildly more positive in those not 
receiving medical therapy for their disease.
Patients receiving romiplostim were evaluated during the 
open-label extension study using a double-blind, placebo-
controlled environment. This study also included assessment 
of those who were able to self-inject.79 Patients completed a Journal of Blood Medicine 2010:1 29
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new 44 question ITP-patient assessment questionnaire, the 
first of its kind, at baseline and at each scheduled visit to 
assess quality of life, burden of disease, as well as outcome 
measurement after treatment.13,80 At baseline, scores were 
comparable between the treatment and placebo groups. 
Although splenectomized patients reported a lower base-
line quality of life when compared to nonsplenectomized 
patients, both groups reported improvements when com-
pared to placebo groups after treatment with romiplostim, 
though splenectomized patients still reported lower values 
when compared to nonsplenectomized. At 24 weeks, those 
who did not respond to romiplostim had decreased values 
in psychological health questions. Patients who continued 
on their concurrent medications had lower scores but there 
were no statistical differences determined.
A large survey conducted in the United Kingdom assessed 
health-related lifestyle among 790 adults and children with 
ITP. The study revealed that one quarter of adults and one 
fifth of children reported missing work or school due to 
fatigue from ITP. Many proclaimed to have difficulty obtain-
ing insurance while others admitted to having elective surgi-
cal procedures delayed as a result of low platelets. Adults and 
children admitted to being suspected of subjection to violence 
due to the many bruises from their illness.81
Another North American survey conducted to assess 
patients’ willingness to accept certain risks or adverse events 
to increase the likelihood of treatment success, avoid the 
need for corticosteroids, or obtain a convenient mode of 
administration was completed by 1542 patients with chronic 
ITP. To obtain a 25% increase in likelihood of achieving an 
appropriate platelet count, patients were willing to accept 
an 18.8% risk for rebound thrombocytopenia. To avoid the 
use of steroids, patients accepted a 20% risk for rebound 
thrombocytopenia and 3.4% risk of blood clot. Interestingly, 
patients were willing to accept a 2% risk of thrombotic event 
and a 13% risk of liver function test abnormalities or rebound 
thrombocytopenia if they could take 1–2 pills per day in 
place of going to a physician office weekly for an injection. 
In fact, 71% of patients stated they would choose pills over 
injections in general.25
Conclusion
To date, long-term management of chronic, refractory ITP 
has been less than satisfactory due to the variable efficacy, 
poor tolerability, and severe side effects associated with 
current treatment options.25 As evidenced from many health-
related quality of life surveys, patients are often troubled not 
only by the medical complications of this disease but also 
the social and psychological impacts. Traditional first line 
therapies for adult chronic ITP are still important agents 
that provide long-term improvements in the majority of 
patients, but they do have their associated adverse effects. 
Patients with relapsing or refractory disease are more likely 
to be affected by toxicities due to the prolonged use. With 
the addition of the TPO-mimetic drugs, romiplostim and 
eltrombopag as treatment options, patients now have an 
alternative to previous therapies. It is important to note that 
these therapies are primarily studied in patients with chronic 
refractory disease who have failed many other treatments. 
These medicines are not designed to be curative and their 
place in earlier treatment of ITP has yet to be established.82 
On the whole, however, these medications appear to be 
promising, effective, and well-tolerated therapeutic agents 
with the potential to improve quality of life and reduce the 
therapy-related toxicities in the treatment of chronic, refrac-
tory immune thrombocytopenic purpura.
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